GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » Net Margin %

Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Net Margin % : 4.36% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Amylyx Pharmaceuticals's Net Income for the three months ended in Dec. 2023 was $4.7 Mil. Amylyx Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $108.4 Mil. Therefore, Amylyx Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was 4.36%.

The historical rank and industry rank for Amylyx Pharmaceuticals's Net Margin % or its related term are showing as below:

AMLX' s Net Margin % Range Over the Past 10 Years
Min: -892.38   Med: -439.72   Max: 12.94
Current: 12.94


AMLX's Net Margin % is ranked better than
85.7% of 1028 companies
in the Biotechnology industry
Industry Median: -159.44 vs AMLX: 12.94

Amylyx Pharmaceuticals Net Margin % Historical Data

The historical data trend for Amylyx Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amylyx Pharmaceuticals Net Margin % Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
- - - -892.38 12.94

Amylyx Pharmaceuticals Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -195.13 2.20 22.47 20.35 4.36

Competitive Comparison of Amylyx Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Amylyx Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's Net Margin % falls into.



Amylyx Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Amylyx Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=49.271/380.786
=12.94 %

Amylyx Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=4.731/108.449
=4.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amylyx Pharmaceuticals  (NAS:AMLX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Amylyx Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
43 Thorndike Street, Cambridge, MA, USA, 02141
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Executives
Joshua B Cohen director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
James M Frates officer: Chief Financial Officer 88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone director C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Gina Mazzariello officer: Chief Legal Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Milne George M Jr director
Margaret Olinger officer: Chief Commercial Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc 10 percent owner 55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v. 10 percent owner EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Isaac Cheng director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Mvil, Llc 10 percent owner 22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901